Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Non-Current Assets: 2020-2024

Historic Non-Current Assets for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $20.4 million.

  • SAB Biotherapeutics' Non-Current Assets rose 230.06% to $70.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.2 million, marking a year-over-year increase of 230.06%. This contributed to the annual value of $20.4 million for FY2024, which is 18.50% down from last year.
  • According to the latest figures from FY2024, SAB Biotherapeutics' Non-Current Assets is $20.4 million, which was down 18.50% from $25.0 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Non-Current Assets ranged from a high of $30.9 million in FY2021 and a low of $20.4 million during FY2024.
  • For the 3-year period, SAB Biotherapeutics' Non-Current Assets averaged around $24.7 million, with its median value being $25.0 million (2023).
  • Per our database at Business Quant, SAB Biotherapeutics' Non-Current Assets spiked by 40.15% in 2021 and then decreased by 18.50% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Non-Current Assets (Yearly) stood at $22.1 million in 2020, then soared by 40.15% to $30.9 million in 2021, then fell by 6.92% to $28.8 million in 2022, then decreased by 13.10% to $25.0 million in 2023, then declined by 18.50% to $20.4 million in 2024.